approaching commercialisation

The success of the phase 2 trial seems like a bit of a no-brainer, afterall they ( surgeons ) have been using these materials successfully on humans for years. the BioMD treatment of patches will improve patient outcomes enourmously.
Upon commercialisation the upfront cost of the raw material is negligable leaving plenty of room for generous margins in a potentially huge market.

This Co sets itself appart from many in the sector,IMO, in that it is not searching for elusive cures or reliant on some sort of breakthru in order to become a viable business. BioMd has a product almost ready for market and the Co is in discussions with third parties in order to get product to market.
Most people are bamboozled by this sector but here is a simple story that makes sense . the next 6-12 months should be good for this sleeping beauty